Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bryolat
- Development stage
- Preclinical
- Lead developer
- Aphios
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
Bryolat is a nanoparticle-based therapy developed by Aphios International for the treatment of HIV-1 latency. It is designed to function as a latency-reversing agent (LRA) as part of a 'shock and kill' strategy aimed at achieving a functional cure for HIV. The drug utilizes bryostatin-1 (or a bryostatin analog), encapsulated in polymer nanospheres using Aphios's proprietary PNC (Polymer Nanospheres/Nanocapsules) technology. The mechanism of action involves the activation of Protein Kinase C (PKC), which induces the expression of latent HIV-1 proviruses in resting CD4+ T cells. This activation makes the infected cells visible to the immune system and susceptible to clearance by antiretroviral therapy or immune-mediated mechanisms. The nanoparticle formulation is intended to enhance the therapeutic index of the bryostatin compound by improving its stability, solubility, and targeted delivery while potentially reducing systemic toxicity.
- Brand names
- Bryolat
02
Targets
HDAC (HDAC family)CD274 (Programmed cell death protein 1 ligand 1)PKC (Protein kinase C family)
Beyond the preview
Go deeper on Bryolat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bryolat.